Eugenie S. Kleinerman, (Editor), holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, (Co-Editor), is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• The genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies.- Genomics and the Immune Landscape of Osteosarcoma.- RECQ DNA Helicases and Osteosarcoma.- Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.- Oncolytic viruses and their potential as a therapeutic opportunity in Osteosarcoma.- Applying Osteosarcoma Immunology to Understand Disease Progression and Assess immunotherapeutic Response.- Targetable intercellular signaling pathways facilitate lung colonization in osteosarcoma.- Wnt Signaling in Osteosarcoma.- Receptor Tyrosine Kinases in Osteosarcoma: 2019 update.- The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets.- Autophagy in OS.- Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs.- Exosomes: Dynamic Mediators of Extracellular Communication in the TumorMicroenvironment.- Comparative Immunology and Immunotherapy of Canine Osteosarcoma.- Index.

Eugenie S. Kleinerman, (Editor), holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, (Co-Editor), is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• The genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies.- Genomics and the Immune Landscape of Osteosarcoma.- RECQ DNA Helicases and Osteosarcoma.- Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.- Oncolytic viruses and their potential as a therapeutic opportunity in Osteosarcoma.- Applying Osteosarcoma Immunology to Understand Disease Progression and Assess immunotherapeutic Response.- Targetable intercellular signaling pathways facilitate lung colonization in osteosarcoma.- Wnt Signaling in Osteosarcoma.- Receptor Tyrosine Kinases in Osteosarcoma: 2019 update.- The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets.- Autophagy in OS.- Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs.- Exosomes: Dynamic Mediators of Extracellular Communication in the TumorMicroenvironment.- Comparative Immunology and Immunotherapy of Canine Osteosarcoma.- Index.

Eugenie S. Kleinerman, (Editor), holds the Mary V. and John A. Reilly Distinguished Chair, and is currently Professor at the University of Texas MD Anderson Cancer Center in the Departments of Pediatrics Research and Cancer Biology. Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particular osteosarcoma, and for pioneering the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for patients with newly diagnosed osteosarcoma or unresponsive relapsed osteosarcoma lung metastases. Her current research interests include developing novel ways to treat sarcoma patients by identifying new therapeutic targets, the properties that influence metastases, the efficacy of dendritic cell vaccines with and without checkpoint inhibitors for osteosarcoma lung metastases, how tumor vessels are formed in Ewing sarcoma and the use of exercise interventions to mitigate chemotherapy-induced cardiotoxicity.Richard Gorlick, (Co-Editor), is currently the Mosbacher Pediatrics Chair of the Department of Pediatrics Patient Care, and Division Head of Pediatrics at the University of Texas MD Anderson Cancer Center. Dr. Gorlick is an internationally recognized expert in pediatric oncology and hematology, whose research and clinical work have focused on sarcomas, tumors that grow in connective tissues including bones, muscles, tendons and cartilage, understanding the mechanisms behind the development and progression of osteosarcoma, as well as targeted therapies and new drugs for childhood cancers.

• The genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies.- Genomics and the Immune Landscape of Osteosarcoma.- RECQ DNA Helicases and Osteosarcoma.- Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma.- Oncolytic viruses and their potential as a therapeutic opportunity in Osteosarcoma.- Applying Osteosarcoma Immunology to Understand Disease Progression and Assess immunotherapeutic Response.- Targetable intercellular signaling pathways facilitate lung colonization in osteosarcoma.- Wnt Signaling in Osteosarcoma.- Receptor Tyrosine Kinases in Osteosarcoma: 2019 update.- The Role of ALDH in the Metastatic Potential of Osteosarcoma Cells and Potential ALDH Targets.- Autophagy in OS.- Fas signaling as a potential target for the treatment of osteosarcoma metastasis in the lungs.- Exosomes: Dynamic Mediators of Extracellular Communication in the TumorMicroenvironment.- Comparative Immunology and Immunotherapy of Canine Osteosarcoma.- Index.